Entering text into the input field will update the search result below

China accepts Zai Lab's biologics license application for neuromuscular disorder drug

Jul. 13, 2022 9:34 AM ETZai Lab Limited (ZLAB)By: Anuron Mitra, SA News Editor

Detailed close up of the national flag of China waving in the wind on a clear day


  • Zai Lab (NASDAQ:ZLAB) on Wednesday said China's drug regulator had accepted the company's biologics license application (BLA) for efgartigimod alfa injection for the treatment of generalized myasthenia gravis (gMG).
  • Myasthenia gravis is a disorder characterized by weakness and

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.